



Systemic Therapy Update

Volume 11, Number 5 *for health professionals who care for cancer patients* May 2008
Website access at <http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate.htm>

INSIDE THIS ISSUE

- **Editor's Choice:** Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts: New Genitourinary Protocol Patient Handouts
- Cancer Drug Manual: **Complete Revision:** Mitoxantrone; **Limited Revision:** Erlotinib, Tretinoin, Chemotherapy Preparation and Stability Chart
- [List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts:](#) **New:** GUBEP, GUBPWRT, GUBPRT, GUFUPRT, GUSCPERT **Revised:** CNAJZRT, GOCXCRT, UGUSORAF, UGUSUNI SAVAC
- Continuing Education – BC Cancer Agency Annual Cancer Conference 2008
- [Website Resources](#)

[IN TOUCH](#) phone list is provided if additional information is needed.

EDITOR'S CHOICE

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

New Genitourinary Protocol Patient Handouts Five new information handouts have been developed for patients undergoing combined modality treatment (chemoradiation therapy). The patient handouts match existing treatment protocols GUBEP, GUBPWRT, GUBPRT, GUFUPRT, GUSCPERT.

This is part of an ongoing effort by the Systemic Therapy Program and the Tumour Groups to provide more information resources for patients. Priorities have been given to develop patient handouts for new treatment programs, combined modality protocols and any protocols that are identified at particular risk for errors. Currently, there are 54 patient protocol handouts available on the BC Cancer Agency website, with more in development. Protocol specific handouts are useful and efficient means of information transfer, which patients can refer back to as frequently as necessary. A recent study at the BC Cancer Agency showed that most patients found them helpful in understanding their treatment plan and supportive medications (general understandability 9.3 out of 10). Protocol handouts may also help prevent errors or unnecessary toxicity by better informing patients about their own care during the treatment course.

CANCER DRUG MANUAL

Mitoxantrone Monograph and Patient Handout have been completely revised. Expert review was provided by Dr. Lyly Le (Genitourinary Tumour Group). Highlights of monograph changes include:

- further details regarding the cardiac toxicity of mitoxantrone
- the potential interaction between quinolone antibiotics and mitoxantrone

Erlotinib Monograph has been updated to include:

- hair and nail change side effects
- a potential interaction between erlotinib and drugs which alter the pH of the GI tract including antacid, H2 blockers, or proton pump inhibitors

Tretinoin Patient Handout has been revised to be consistent with the monograph, with the deletion of the statement pertaining to sterility and menopause.

Chemotherapy Preparation and Stability Chart has been updated:

- **Mitoxantrone:**
 - information on more brands and vial sizes has been added
 - brand specific stability data has been updated
 - the need to protect the final product from light has been clarified
- **Leucovorin:** information on the Novopharm brand product has been added
- **Special Cautions/Note Column:** the following notes have been deleted to reduce duplication of information redundancy as indicated below:
 - category of extravasation hazard for the drug (available in drug monographs and BC Cancer Agency extravasation policy)
 - need to protect from light (listed in vial column or final product column)
 - overfill of vial (replaced by information on reconstitution device in the vial column)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New and revised protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indication Request) approval are prefixed with the letter **U**.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GUBEP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy for Intermediate Risk Non-Seminomatous Testicular Cancer using Bleomycin, Etoposide and Cisplatin
GUBPWRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Locally Advanced Bladder Cancer with Weekly Cisplatin and Concurrent Radiation
GUBPRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Locally Advanced Bladder Cancer Using Concurrent Cisplatin with Radiation
GUFUPRT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and Cisplatin with Radiation
GUSCPERT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy of Genitourinary Small Cell Tumors with a Platin and Etoposide with Radiation

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNAJZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Frequency of neuroimaging clarified</i>	Concomitant and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
GOCXCRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Change in eligibility criteria</i>	Treatment of High Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent Cisplatin and Radiation
UGUSORAF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Platelet in dose modification table clarified</i>	Therapy for Renal Cell Carcinoma Using Sorafenib (NEXAVAR®)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UGUSUNI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Platelet in dose modification table clarified</i>	Palliative Therapy for Renal Cell Carcinoma Using Sunitinib (SUTENT®)
SAVAC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Vincristine dose clarified</i>	Adjuvant therapy for patients with newly diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumour or Rhabdomyosarcoma using Vincristine, Doxorubicin and Cyclophosphamide

CONTINUING EDUCATION

BC Cancer Agency Annual Cancer Conference 2008 will be held on **20-22 November** at the Westin Bayshore Resort & Marina in Vancouver. This year's theme will be ***Survivorship: Creating It, Managing It.***

Stay tuned for more information about this exciting conference.

WEBSITE RESOURCES

The following are available on the BC Cancer Agency website (www.bccancer.bc.ca) under the Health Professionals Info section:

REIMBURSEMENT AND FORMS: BENEFIT DRUG LIST, CLASS II, COMPASSIONATE ACCESS PROGRAM (UNDESIGNATED INDICATION)	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
CANCER DRUG MANUAL	www.bccancer.bc.ca/cdm
CANCER MANAGEMENT GUIDELINES	www.bccancer.bc.ca/CaMgmtGuidelines
CANCER CHEMOTHERAPY PROTOCOLS	www.bccancer.bc.ca/ChemoProtocols
CANCER CHEMOTHERAPY PRE-PRINTED ORDERS	www.bccancer.bc.ca/ChemoProtocols under the index page of each tumour site
SYSTEMIC THERAPY PROGRAM POLICIES	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
UNCONVENTIONAL CANCER THERAPIES MANUAL	under Patient/Public Info, Unconventional Therapies

Editorial Review Board

Mário de Lemos, PharmD, MSc(Oncol) (Editor)
 Caroline Lohrisch, MD
 Johanna Den Duyf, MA
 Judy Oliver, BScN, MEd

Beth Morrison, MLS
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC CANCER AGENCY	(604) 877-6000	Toll-Free 1-(800) 663-3333
COMMUNITIES ONCOLOGY NETWORK	Ext 2744	jvenkate@bccancer.bc.ca
EDUCATION RESOURCE NURSE	Ext 2638	nursinged@bccancer.bc.ca
NURSING PROFESSIONAL PRACTICE	Ext 2623	ilundie@bccancer.bc.ca
PHARMACY PROFESSIONAL PRACTICE	Ext 2247	gconcon@bccancer.bc.ca
PROVINCIAL SYSTEMIC THERAPY PROGRAM	Ext 2247	gconcon@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK PHARMACIST	Ext 6277	lkovacic@bccancer.bc.ca
DRUG INFORMATION	Ext 6275	druginfo@bccancer.bc.ca
LIBRARY/CANCER INFORMATION	1-(888)-675-8001	requests@bccancer.bc.ca
	Ext 8003	
OSCAR HELP DESK	1-(888)-355-0355	oscar@bccancer.bc.ca
	Fax (604) 708-2051	
COMPASSIONATE ACCESS PROGRAM OFFICE	Ext 6277	cap_bcca@bccancer.bc.ca
(FORMERLY UNDESIGNATED DRUG APPLICATION OFFICE)	Fax (604) 708-2026	
UPDATE EDITOR	Ext 2288	mdelemos@bccancer.bc.ca
CENTRE FOR THE SOUTHERN INTERIOR (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
FRASER VALLEY CENTRE (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
VANCOUVER CENTRE (VCC)	(604) 877-6000	Toll-Free 1-(800) 663-3333
VANCOUVER ISLAND CENTRE (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322